Tulane University is actively seeking companies interested in commercializing novel compounds
which are effective antagonists of ghrelin, growth hormone releasing peptide and the growth
hormone secretagogue receptor.
Provides effective treatment of hormonally functional endocrine or non-endocrine tumors,
including breast, prostate, pituitary, functional ectopic neuroendocrine, carcinoid, pancreatic and
These peptide compounds are relatively short (less than 10 amino acids) and act at the level of
the central nervous system. Peptides are generally easy to manufacture and purify and tend to
have very low toxicity profiles.
This technology has been tested extensively in vitro and in vivo in a rat model, with results
strongly supporting the efficacy of the compounds. Laboratory work is ongoing to produce more
effective species of these compounds.
Cyril Bowers, Ph.D., David Coy, Ph.D., Simon Hocart, Ph.D., Gloria Tannenbaum, Ph.D.
Tulane Technology Transfer and Intellectual Property Development, New Orleans, LA 70112 504-988-6962 email@example.com